

DAPAGLIFLOZIN tablets (Forxiga®) for treating chronic kidney disease

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of DAPAGLIFLOZIN tablets (Forxiga®) for treating chronic kidney disease

GREY

Dapagliflozin has been granted a license extension and is now indicated in adults for the treatment of chronic kidney disease (CKD)^[1].

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of CKD should continue to follow national guidance, local pathways and local formulary choices.

- > NICE Guideline [NG203]: [Chronic kidney disease: assessment and management](#) (last updated 25 August 2021)
- > NICE Pathway: [Chronic kidney disease](#) (updated 25 August 2021)
- > NICE Clinical Knowledge Summary: [Chronic kidney disease](#) (update August 2021)

References

1. AstraZeneca UK Ltd. Summary of Product Characteristics; [Forxiga 10mg film coated tablets](#), 05 August 2021. Accessed online 23 September 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.